Title:Metabolic Syndrome in HIV-patients in Antiretroviral Therapy
Volume: 18
Issue: 6
Author(s): Daniel Vargas-Pacherrez*, Helma P. Cotrim, Leonardo Pires, Vitor Cunha, Vitor Coelho, Carlos Brites and Carla Daltro
Affiliation:
- LAPI, Laboratório de Pesquisa em Infectologia. Complexo Hospitalar Professor Edgard Santos, Faculdade de Medicina da Bahia - Universidade Federal da Bahia (UFBA), Bahia,Brazil
Keywords:
Acquired immunodeficiency syndrome, metabolic syndrome, human immunodeficiency virus, antiretroviral therapy,
metabolic disorders, prevalence
Abstract: Introduction: The global prevalence of metabolic syndrome (MS) among people living
with HIV/AIDS varies from 20% to 33%.
Objective: to estimate the prevalence of metabolic syndrome and associated factors in a group of
HIV-infected patients on antiretroviral therapy.
Methods: This is a cross-sectional study with HIV-infected patients from a reference center in Bahia,
Brazil. We evaluated clinical, socio-demographic and anthropometric data. MS was defined according
to the guidelines of International Diabetes Federation.
Results: We evaluated 152 patients with mean age of 47.3±11.6 years, 59.2% male. The main comorbidities
detected were diabetes (3.3%) hypertriglyceridemia (9.3%) and metabolic syndrome
(MS,38.2%). Patients with MS were predominantly women (55.2% vs 31.9%; p=0.005), older
[52.1 (10.4) vs 44.3 (11.3); p<0.001], and had overweight (74.1% vs 23.4%; p<0.001). After multivariate
analysis MS remained associated with age (OR = 1.076; 95% CI: 1.030 – 1.125), female sex
(OR = 2.452; 95% CI: 1.114 – 5.374) and family history of hypertension (OR = 3.678; 95% CI:
1.431 – 9.395).
Conclusion: Almost half of the HIV-infected patients in Bahia presents with MS which seems to be
driven by classical risk factors.
